Report Store | Pharma intelligence
  • My Account
    • 0Shopping Cart
  • $0.00
  • Disease analysis
    • Anemias
    • Bacterial infections
    • Bleeding disorders
    • Brain Cancer
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Cerebrovascular diseases
    • Dermatology
    • Diabetes and diabetic complications
    • Gastroenterology
    • Gastrointestinal cancer
    • Head and Neck Cancer
    • Hypertension
    • Immunology and Inflammation
    • Infectious Diseases
    • Ischemic heart disease
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Oncology overview
    • Market Spotlight
    • Mens Health
    • Neurology
    • Oncology
    • Ophthalmology
    • Other Hematological Cancers
    • Other metabolic diseases
    • Other Solid Cancers
    • Pain
    • Psychiatry
    • Respiratory
    • Rheumatology
    • Skin cancer
    • Thrombosis
    • Urological cancer
    • Vaccines
    • Viral infections
    • Women’s Health
  • Strategy analysis
    • Bleeding disorders
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Commercial Strategy
    • Dealmaking and R&D
    • Head and Neck Cancer
    • Hot Topics
    • Infectious Diseases
    • KOL Insight
    • Leukemia
    • Lung Cancer
    • Manufacturing
    • Market Access
    • Neurology
    • Oncology
    • Outsourcing
    • Pricing & Reimbursement
    • R&D
    • Regulatory & Therapeutic Area
    • Trends
    • Urological cancer
  • Company analysis
    • Big Pharma
    • Emerging Pharma
    • Hot Topics
    • Japan Pharma
    • M&A Analysis
    • Mid Pharma
  • Drug analysis
    • A
    • B-C
    • D-F
    • G-L
    • M-O
    • P-R
    • S-T
    • U-Z
  • MedTech analysis
    • Allergy
    • Autoimmune / Immunology
    • Cardiovascular
    • Dermatology
    • Endocrine
    • ENT / Dental
    • Gastroenterology
    • Hearing
    • Hematology
    • Infectious Diseases
    • Metabolic
    • Neurology
    • Obstetrics / Gynecology
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Osteoporosis
    • Psychiatry
    • Renal
    • Respiratory
    • Rheumatology
    • Urology
  • Opinion & analysis
    • Business Development
    • Business Management
    • Clinical Trials
    • Digital Health
    • Cybersecurity
    • Compliance & Risk
    • Digital patient management
    • Digital policy & regulation
    • Finance & Pricing
    • Healthcare Innovation
    • ICT and Health
    • Leadership
    • Legislation Regulation & Policy
    • Market Access
    • Market Intelligence
    • Medical
    • Pharmaceutical Device
    • Pharmaceutical Research
    • Strategy & Innovation
    • Tech companies & Data
    • Tech & Pharma
  • Blogs
  • Search
  • Menu
You are here: Home > Strategy analysis

Strategy analysis


  • Sort by Price
    • Default
    • Custom
    • Name
    • Price
    • Date
    • Popularity (sales)
    • Average rating
    • Relevance
    • Random
    • Product ID
  • Click to order products ascending
  • Display 30 Products per page
    • 15 Products per page
    • 30 Products per page
    • 45 Products per page
  • The Contract Biomanufacturing Market Outlook to 2017

    $5,000.00

    The biologic drug market is growing at nearly twice the pace of the overall pharmaceutical market, driven by major therapeutic fields under research such as oncology and autoimmune diseases. The forecasted 20% annual increase in biologic active pharmaceutical ingredient (API) demand between 2011 and 2017 combined with the growth of biosimilars will generate a positive environment for the biologics contract manufacturing organization (CMO) market to grow at 9% per year over the same period.

    November 3, 2016
    Find out more
  • Surviving a Scandal: How to Expect the Unexpected

    $5,000.00

    The Institute of Crisis Management defines a crisis as “any problem or disruption that triggers negative stakeholder reaction and that could impact the organization’s financial strength and ability to do what it does.” In the pharmaceutical setting, a crisis could mean an adverse clinical trial event, the bankruptcy of an essential service provider, or a serious product recall. It could be an event that is within the company’s control and has been mishandled, or an external situation that forces the business to change its strategic course, either temporarily or permanently.

    November 3, 2016
    Find out more
  • CRO League Tables: Acquisition, Competition, and Privatization

    $5,000.00

    Over the past 12 months, the clinical research outsourcing (CRO) industry has taken its next decisive steps in the evolution of a business making its mark in drug development.

    November 3, 2016
    Find out more
  • Value-Based Pricing – Evolution Rather Than Revolution

    $5,000.00

    A new value-based assessment (VBA) process is scheduled to come into effect in the UK in late 2014. There have been significant delays in determining how this would work in practice, reflecting VBA’s complexity.

    November 4, 2016
    Find out more
  • PD-1/L1 Immunotherapies: Historical Sales and Market Trend Analysis Report

    $7,500.00

    Bristol-Myers Squibb’s (BMS) Opdivo (nivolumab) has outpaced Merck’s Keytruda (pembrolizumab) primarily
    in non-small cell lung cancer (NSCLC) because of its early approval in squamous NSCLC, updated National
    Comprehensive Cancer Network (NCCN) guidelines in 2015,

    December 22, 2016
    Find out more
  • copd-pricing-reimbursement-and-access_160221_10-2016

    Chronic Obstructive Pulmonary Disease (COPD): Market Access Pricing & Reimbursement

    $7,000.00

    Long-acting beta 2 agonist/long-acting muscarinic antagonist (LABA/LAMA) combination inhalers have been gaining traction due to an expanding evidence base for their wider use, and competitive pricing.

    October 17, 2016
    Find out more
  • Datamonitor Oncology Pathways in the US - Friend or Foe for Pharma

    Oncology Pathways in the US – Friend or Foe for Pharma

    $7,500.00

    This strategy report focuses on Oncology Pathways in the US including management of oncology costs, oncology clinical pathway programs and developers, impact of pathways on oncology, and the future of oncology pathways. 

    July 31, 2015
    Find out more
  • Datamonitor Accountable Care Organizations - What Impact on Pharma

    Accountable Care Organizations – What Impact on Pharma

    $7,500.00

    This strategy report focuses Accountable Care Organizations and what impact they will have on pharma including an evaluation of ACOs’ structures, sizes, cultures, and risks.

    July 16, 2015
    Find out more
  • Immuno-Oncology Overview

    $7,500.00

    Immuno-oncology is an area of medicine that focuses on the development of therapies that improve the body’s ability to generate an immune response against cancer (Eggermont and Finn, 2012).

    December 13, 2017
    Find out more
Page 12 of 12
Page 12 of 12«‹101112
  • Home
  • Terms and Conditions
  • Refund policy
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • About Us
  • Discounts
  • Market Spotlight – Reports
  • twitter
  • linkedin
  • Sitemap
Copyright © 2022 Pharma Intelligence UK Limited Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London, SW1P 1WG. Pharma Intelligence UK Limited is part of the Pharma Intelligence Group.

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Call Back
Scroll to top